|
|
Blood, 15 January 2005, Vol. 105, No. 2, pp. 489-495.
Prepublished online as a Blood First Edition Paper on September 9, 2004; DOI 10.1182/blood-2004-06-2156.
 Previous Article | Next Article 
Submitted June 7, 2004
Accepted August 25, 2004
Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin's lymphoma: increased interferon- / -inducible gene expression, without significant toxicity
Jonathan W Friedberg*, Helen Kim, Mary McCauley, Edith M Hessel, Paul Sims, David C Fisher, Lee M Nadler, Robert L Coffman, and Arnold S Freedman
James P. Wilmot Cancer Center, University of Rochester, Rochester, NY, USA
Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Dynavax Technologies, Berkley, CA, USA
* Corresponding author; email: jonathan_friedberg{at}urmc.rochester.edu.
CpG oligodeoxynucleotides (CpG-ODN) affect innate and adaptive immune responses, including antigen presentation, costimulatory molecule expression, dendritic cell maturation, and induction of cytokines enhancing ADCC. We conducted a phase I study evaluating 4 dose levels of a CpG-ODN (1018 ISS, Dynavax Technologies) with rituximab in 20 patients with relapsed NHL. Patients received CpG weekly x 4 beginning after the second of 4 rituximab infusions. Adverse events were minimal. Quantitative PCR measurements of a panel of genes inducible by CpG-ODN and interferons were performed on blood samples collected prior to and 24 hours after CpG. A dose-related increase was measured in the expression of several IFN-inducible genes following CpG, and correlated with serum levels of 2-5-OAS, a validated interferon response marker. Genes induced selectively by IFN-gamma were not significantly induced by CpG. In conclusion, we have defined a set of gene expression markers that provide a sensitive measure of patient biological responses to CpG therapy in a dose-related manner. Moreover, all of the genes significantly induced by this CpG are regulated by type-1 interferons, providing insights into the dominant immune mechanisms in humans. CpG treatment had no significant toxicity, providing rationale for further testing of this exciting combination immunotherapy approach to NHL.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
K. Tse and A. A Horner
Update on toll-like receptor-directed therapies for human disease
Ann Rheum Dis,
November 1, 2007;
66(suppl_3):
iii77 - iii80.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Leonard, B. K. Link, C. Emmanouilides, S. A. Gregory, D. Weisdorf, J. Andrey, J. Hainsworth, J. A. Sparano, D. E. Tsai, S. Horning, et al.
Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non Hodgkin's Lymphoma
Clin. Cancer Res.,
October 15, 2007;
13(20):
6168 - 6174.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Maddipatla, F. J. Hernandez-Ilizaliturri, J. Knight, and M. S. Czuczman
Augmented Antitumor Activity against B-Cell Lymphoma by a Combination of Monoclonal Antibodies Targeting TRAIL-R1 and CD20
Clin. Cancer Res.,
August 1, 2007;
13(15):
4556 - 4564.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Faith, E. Peek, J. McDonald, Z. Urry, D. F. Richards, C. Tan, G. Santis, and C. Hawrylowicz
Plasmacytoid Dendritic Cells from Human Lung Cancer Draining Lymph Nodes Induce Tc1 Responses
Am. J. Respir. Cell Mol. Biol.,
March 1, 2007;
36(3):
360 - 367.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Fujii, J. D. Trudeau, D. T. Teachey, J. D. Fish, S. A. Grupp, K. R. Schultz, and G. S. D. Reid
In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotides
Blood,
March 1, 2007;
109(5):
2008 - 2013.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Damiano, R. Caputo, R. Bianco, F. P. D'Armiento, A. Leonardi, S. De Placido, A. R. Bianco, S. Agrawal, F. Ciardiello, and G. Tortora
Novel Toll-Like Receptor 9 Agonist Induces Epidermal Growth Factor Receptor (EGFR) Inhibition and Synergistic Antitumor Activity with EGFR Inhibitors
Clin. Cancer Res.,
January 15, 2006;
12(2):
577 - 583.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Friedberg
Unique Toxicities and Resistance Mechanisms Associated with Monoclonal Antibody Therapy
Hematology,
January 1, 2005;
2005(1):
329 - 334.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
